Over 95% of commercially insured patients paid $0 for IDELVION through the co-pay program in 2020.4
CSL Behring is committed to providing treatment and support services that make a meaningful difference in the lives of people with bleeding disorders.
Resources are available to help your eligible patients get the treatment they need for hemophilia B, including:
References: 1. Data on file. Available from CSL Behring as DOF IDL-006. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 3. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127(14):1761-1769. doi:10.1182/blood-2015-09-669234. 4. Data on file. Available from CSL Behring as DOF IDL-009.